Recombinant adenovirus expressing a dendritic cell‑targeted melanoma surface antigen for tumor‑specific immunotherapy in melanoma mice model

Guo,Li‑Li; Wang,Gang‑Cheng; Li,Peng‑Jie; Wang,Cui‑Mei; Liu,Lin‑Bo

doi:10.3892/etm.2018.6085

Recombinant adenovirus expressing a dendritic cell‑targeted melanoma surface antigen for tumor‑specific immunotherapy in melanoma mice model

Authors:
- Li‑Li Guo
- Gang‑Cheng Wang
- Peng‑Jie Li
- Cui‑Mei Wang
- Lin‑Bo Liu
View Affiliations

Affiliations: Department of Plastic Surgery, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: April 23, 2018 https://doi.org/10.3892/etm.2018.6085
Pages: 5394-5402

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Viral vectors represent a potential strategy for the treatment of human malignant tumors. Currently, recombinant adenovirus vectors are commonly used as gene therapy vehicles, as it possesses a proven safety profile in normal human cells. The recombinant adenovirus system has an ability to highly express exogenous genes and increase the stability of the carrier, which is only transiently expressed in the host cell genome, without integrating. Malignant melanoma cells are produced by the skin, and melanocyte tumors that exhibit higher malignant degrees lead to earlier transfer and higher mortality. In the present study, a recombinant adenovirus (rAd) was generated to express Anti‑programmed death‑1 (rAd‑Anti‑PD‑1) and used to investigate the efficacy in melanoma cells and tumors. The results demonstrated that B16‑F10 cell growth was significantly inhibited and the apoptosis incidence rate was markedly promoted following rAd‑PD‑1 treatment. The present study demonstrated that the production of α and β interferon was increased, which led to the induction of dendritic cell (DCs) maturation in rAd‑anti‑PD‑1‑treated mice. The present study indicated that rAd‑anti‑PD‑1 exhibited the ability to generate more cluster of differentiation (CD)4+CD8+ T cells and induce a PD‑1‑specific cytotoxic T lymphocyte through DC‑targeted surface antigens in mice. This resulted in a further enhanced recognition of melanoma cells due to DCs being targeted by the rAd‑anti‑PD‑1‑encoded PD‑1. Notably, mice treated with the rAd‑anti‑PD‑1‑targeted PD‑1 demonstrated an improved protection compared with tumor‑bearing mice from the challenge group treated with a recombinant gutless adenovirus and Anti‑PD‑1. In conclusion, the present study demonstrated that targeting the melanoma surface antigens via the rAd‑anti‑PD‑1‑infected tumor cells enhanced the ability of recombinant adenovirus to induce a potent tumor‑inhibitory effect and antigen‑specific immune response.

View Figures

View References

1	Ungureanu L, Botar Jid C, Candrea E, Cosgarea R and Senila SC: The role of lymph node ultrasound evaluation in melanoma-review of the literature. Med Ultrasono. 18:224–230. 2016. View Article : Google Scholar
2	Liu H, Yan Y and Jiang CM: Primary malignant melanoma of the esophagus with unusual endoscopic findings: A case report and literature review. Medicine (Baltimore). 95:e34792016. View Article : Google Scholar : PubMed/NCBI
3	Linertová R, Valcárcel-Nazco C and Lacalle-Remigio JR: Management of benign melanocytic lesions as a melanoma prevention. Systematic review. Med Clin (Barc). 147:162–170. 2016.(In Spanish). View Article : Google Scholar : PubMed/NCBI
4	Cazes A and Ronai ZA: Metabolism in melanoma metastasis. Pigment Cell Melanoma Res. 29:118–119. 2016. View Article : Google Scholar : PubMed/NCBI
5	Martínez-Esteve A, Álvarez-Pérez RM, Caballero-Gullón L, Sancho-Márquez MP and Borrego-Dorado I: Breast metastasis from melanoma mimicking inflammatory breast cancer. Eur J Nuc Med Mol Imaging. 43:389–390. 2016. View Article : Google Scholar
6	Margolin KA: Brain metastases in melanoma: Moving toward curing the incurable. J Oncol Pract. 12:545–546. 2016. View Article : Google Scholar : PubMed/NCBI
7	Chukwueke U, Batchelor T and Brastianos P: Management of brain metastases in patients with Melanoma. J Oncol Pract. 12:536–542. 2016. View Article : Google Scholar : PubMed/NCBI
8	Schwartz H, Blacher E, Amer M, Livneh N, Abramovitz L, Klein A, Ben-Shushan D, Soffer S, Blazquez R, Barrantes-Freer A, et al: Incipient melanoma brain metastases instigate astrogliosis and neuroinflammation. Cancer Res. 76:4359–4371. 2016. View Article : Google Scholar : PubMed/NCBI
9	Sharma G, Lian CG, Lin WM, Amin-Mansour A, Jané-Valbuena J, Garraway L, Bao W, Yoon CH and Ibrahim N: Distinct genetic profiles of extracranial and intracranial acral melanoma metastases. J Cutan Pathol. 43:884–891. 2016. View Article : Google Scholar : PubMed/NCBI
10	Luo M and Fu L: The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: Some chemotherapeutical drugs may finally work through immune response. Oncotarget. 7:29794–29803. 2016. View Article : Google Scholar : PubMed/NCBI
11	Fang XN and Fu LW: Predictive efficacy biomarkers of programmed cell death 1/programmed cell death 1 ligand blockade therapy. Recent Pat Anticancer Drug Discov. 11:141–151. 2016. View Article : Google Scholar : PubMed/NCBI
12	Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, Gorecka MA, de Haan AF, Mulders P, Punt CJ, et al: PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 35:169–178. 2012. View Article : Google Scholar : PubMed/NCBI
13	Sakthivel P, Gereke M and Bruder D: Therapeutic intervention in cancer and chronic viral infections: Antibody mediated manipulation of PD-1/PD-L1 interaction. Rev Recent Clin Trials. 7:10–23. 2012. View Article : Google Scholar : PubMed/NCBI
14	Lee JJ, Chan A and Tang T: Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma. Acta Oncol. 55:519–520. 2016. View Article : Google Scholar : PubMed/NCBI
15	Karakatsanis S, Bertsias G, Roussou P and Boumpas D: Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: Brief review. Hematol Oncol. 32:113–119. 2014. View Article : Google Scholar : PubMed/NCBI
16	Huang B, Chen L, Bao C, Sun C, Li J, Wang L and Zhang X: The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: A systematic review and meta-analysis. Onco Targets Ther. 8:2617–2625. 2015.PubMed/NCBI
17	Ferris R: PD-1 targeting in cancer immunotherapy. Cancer. 119:E1–E3. 2013. View Article : Google Scholar : PubMed/NCBI
18	Yan F, Zheng Y and Huang L: Adenovirus-mediated combined anti-angiogenic and pro-apoptotic gene therapy enhances antitumor efficacy in hepatocellular carcinoma. Oncol Lett. 5:348–354. 2013. View Article : Google Scholar : PubMed/NCBI
19	Sinkovics JG and Horvath JC: Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz). 56 Suppl 1:S3–S59. 2008. View Article : Google Scholar
20	Zhang MM, Yan LN, Li DH, Gou XH, Liu JW, Su Z, Han L and Zhao LY: Inhibition of adenovirus-mediated gene transfer of antisense matrix metalloproteinase-2 on hepatocellular carcinoma growth in vivo. Zhonghua Gan Zang Bing Za Zhi. 13:671–674. 2005.(In Chinese). PubMed/NCBI
21	Thomas AA, Ernstoff MS and Fadul CE: Immunotherapy for the treatment of glioblastoma. Cancer J. 18:59–68. 2012. View Article : Google Scholar : PubMed/NCBI
22	Larsen CJ: Cellular immunotherapy and glioblastoma: A hopeful treatment? Bull Cancer. 98:4572011.(In French). PubMed/NCBI
23	Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R and Martuza RL: Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res. 67:9371–9379. 2007. View Article : Google Scholar : PubMed/NCBI
24	Husain SR, Behari N, Kreitman RJ, Pastan I and Puri RK: Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. Cancer Res. 58:3649–3653. 1998.PubMed/NCBI
25	Debinski W, Gibo DM, Obiri NI, Kealiher A and Puri RK: Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotechnol. 16:449–453. 1998. View Article : Google Scholar : PubMed/NCBI
26	Bera TK, Viner J, Brinkmann E and Pastan I: Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Cancer Res. 59:4018–4022. 1999.PubMed/NCBI
27	Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW and Vitetta ES: Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites. Cancer Res. 51:5876–5880. 1991.PubMed/NCBI
28	Neves Costa M, Giakoustidis A, Stamp G, Gaya A and Mudan S: Extended survival after complete pathological response in metastatic pancreatic ductal adenocarcinoma following induction chemotherapy, chemoradiotherapy, and a novel immunotherapy agent, IMM-101. Cureus. 7:e4352015.PubMed/NCBI
29	Li J, Chen QY, He J, Li ZL, Tang XF, Chen SP, Xie CM, Li YQ, Huang LX, Ye SB, et al: Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Oncoimmunology. 4:e9765072015. View Article : Google Scholar : PubMed/NCBI
30	Wang X, Bayer ME, Chen X, Fredrickson C, Cornforth AN, Liang G, Cannon J, He J, Fu Q, Liu J, et al: Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. J Surg Oncol. 111:862–867. 2015. View Article : Google Scholar : PubMed/NCBI
31	Nazarkina ZhK and Laktionov PP: Preparation of dendritic cells for cancer immunotherapy. Biomed Khim. 61:30–40. 2015.(In Russian). View Article : Google Scholar : PubMed/NCBI
32	Dias JD, Hemminki O, Diaconu I, Hirvinen M, Bonetti A, Guse K, Escutenaire S, Kanerva A, Pesonen S, Löskog A, et al: Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther. 19:988–998. 2012. View Article : Google Scholar : PubMed/NCBI
33	LaRocca CJ, Han J, Gavrikova T, Armstrong L, Oliveira AR, Shanley R, Vickers SM, Yamamoto M and Davydova J: Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer. Surgery. 157:888–898. 2015. View Article : Google Scholar : PubMed/NCBI
34	Gerhardt A, Usener D, Keese M, Sturm J, Schadendorf D and Eichmuller S: Tissue expression and sero-reactivity of tumor-specific antigens in colorectal cancer. Cancer Lett. 208:197–206. 2004. View Article : Google Scholar : PubMed/NCBI
35	Santin AD, Bellone S, Palmieri M, Bossini B, Cane' S, Bignotti E, Roman JJ, Cannon MJ and Pecorelli S: Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer. Int J Gynecol Cancer. 14:64–75. 2004. View Article : Google Scholar : PubMed/NCBI
36	Morotomi N, Fukuda K, Nakano M, Ichihara S, Oono T, Yamazaki T, Kobayashi N, Suzuki T, Tanaka Y and Taniguchi H: Evaluation of intestinal microbiotas of healthy Japanese adults and effect of antibiotics using the 16S ribosomal RNA gene based clone library method. Biol Pharm Bull. 34:1011–1020. 2011. View Article : Google Scholar : PubMed/NCBI
37	Gustafsson RK, Engdahl EE and Fogdell-Hahn A: Development and validation of a Q-PCR based TCID50 method for human herpesvirus 6. Virol J. 9:3112012. View Article : Google Scholar : PubMed/NCBI
38	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
39	Fukui A, Muragaki Y, Saito T, Maruyama T, Nitta M, Ikuta S and Kawamata T: Volumetric analysis using low-field intraoperative magnetic resonance imaging for 168 newly diagnosed supratentorial glioblastomas: Effects of extent of resection and residual tumor volume on survival and recurrence. World Neurosurg. 98:73–80. 2017. View Article : Google Scholar : PubMed/NCBI
40	The Guide for the Care and Use of Laboratory Animals. ILAR J 57: NP, 2016.40. Greaves MF and Brown G: Purification of human T and B lymphocytes. J Immunol. 112:420–423. 1974.PubMed/NCBI
41	Shiono H and Ito Y: Novel method for continuous cell separation by density gradient centrifugation: Evaluation of a miniature separation column. Prep Biochem Biotechnol. 33:87–100. 2003. View Article : Google Scholar : PubMed/NCBI
42	Ting WH, Chien MN, Lo FS, Wang CH, Huang CY, Lin CL, Lin WS, Chang TY, Yang HW, Chen WF, et al: Association of cytotoxic t-lymphocyte-associated protein 4 (CTLA4) gene polymorphisms with autoimmune thyroid disease in children and adults: Case-control study. PloS One. 11:e01543942016. View Article : Google Scholar : PubMed/NCBI
43	Zamarin D, Vigil A, Kelly K, Garcia-Sastre A and Fong Y: Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther. 16:796–804. 2009. View Article : Google Scholar : PubMed/NCBI
44	Allegra M, Zaragkoulias A, Vorgia E, Ioannou M, Litos G, Beug H and Mavrothalassitis G: Semaphorin-7a reverses the ERF-induced inhibition of EMT in Ras-dependent mouse mammary epithelial cells. Mol Biol Cell. 23:3873–3881. 2012. View Article : Google Scholar : PubMed/NCBI
45	Youlin K, Jian K, Siming L, Li Z, Weiyang H, Chaodong L and Xin G: Potent anti-prostate cancer immune response induced by dendritic cells transduced with recombinant adenoviruses encoding 4-1BBL combined with cytokine-induced killer cells. Immunotherapy. 7:13–20. 2015. View Article : Google Scholar : PubMed/NCBI
46	Leisegang M, Kammertoens T, Uckert W and Blankenstein T: Targeting human melanoma neoantigens by T cell receptor gene therapy. J Clin Invest. 126:854–858. 2016. View Article : Google Scholar : PubMed/NCBI
47	Braybrooke JP, Slade A, Deplanque G, Harrop R, Madhusudan S, Forster MD, Gibson R, Makris A, Talbot DC, Steiner J, et al: Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res. 11:1512–1520. 2005. View Article : Google Scholar : PubMed/NCBI
48	Zou W, Luo C, Zhang Z, Liu J, Gu J, Pei Z, Qian C and Liu X: A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene. 23:457–464. 2004. View Article : Google Scholar : PubMed/NCBI
49	Hernández-Alcoceba R, Sangro B and Prieto J: Gene therapy of liver cancer. Ann Hepatol. 6:5–14. 2007.PubMed/NCBI
50	Moss JA: Gene therapy review. Radiol Technol. 86:155–180; quiz 181–184. 2014.PubMed/NCBI
51	Eibel B, Markoski MM, Rodrigues CG, Dipp T, de Salles FB, Giusti II, Nardi NB, Plentz RD and Kalil RA: VEGF gene therapy cooperatively recruits molecules from the immune system and stimulates cell homing and angiogenesis in refractory angina. Cytokine. 91:44–50. 2017. View Article : Google Scholar : PubMed/NCBI
52	Sharma A, Mathew Easow M, Sriganesh V and Reiss UM: Gene therapy for haemophilia. Cochrane Database Syst Rev. 12:CD0108222016.PubMed/NCBI
53	Hammer A and Steiner S: Gene therapy for therapeutic angiogenesis in peripheral arterial disease-a systematic review and meta-analysis of randomized, controlled trials. VASA. 42:331–339. 2013. View Article : Google Scholar : PubMed/NCBI
54	Kumar MS, Masthan KM, Babu NA and Dash KC: Gene therapy in oral cancer: A review. J Clin Diagn Res. 7:1261–1263. 2013.PubMed/NCBI
55	Koirala A, Conley SM and Naash MI: A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium. Biomaterials. 34:7158–7167. 2013. View Article : Google Scholar : PubMed/NCBI
56	Kim YS, Hwang KA, Go RE, Kim CW and Choi KC: Gene therapy strategies using engineered stem cells for treating gynecologic and breast cancer patients (Review). Oncol Rep. 33:2107–2112. 2015. View Article : Google Scholar : PubMed/NCBI
57	Watanabe M, Nasu Y and Kumon H: Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review). Oncol Lett. 7:595–601. 2014. View Article : Google Scholar : PubMed/NCBI
58	Ludlow SP, Andrews S, Pasikhova Y and Hill E: New-onset toxicity with programmed death-1 inhibitor rechallenge. Melanoma Res. 26:316–318. 2016. View Article : Google Scholar : PubMed/NCBI
59	Ansell SM: Where do programmed death-1 inhibitors fit in the management of malignant lymphoma? J Oncol Pract. 12:101–106. 2016. View Article : Google Scholar : PubMed/NCBI
60	Villasboas JC and Ansell S: Checkpoint inhibition: Programmed cell death 1 and programmed cell death 1 ligand inhibitors in Hodgkin lymphoma. Cancer J. 22:17–22. 2016. View Article : Google Scholar : PubMed/NCBI